Wall Street is positive on Pardes Biosciences Inc (PRDS). On average, analysts give PRDS a Buy rating. The average price target is $4.083, which means analysts expect the stock to add by 168.62% over the next twelve months. That average ranking earns PRDS an Analyst Rating of 26, which is better than 26% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating PRDS a Buy today. Find out what this means to you and get the rest of the rankings on PRDS!